Amount of funding: Direct costs budgeted for the entire period of performance will not exceed $600,000. Direct costs for a Therapeutic Idea Award – Biomarker Option should not exceed $750,000.
Purpose: The FY23 ALSRP Therapeutic Idea Award supports the initial exploration of innovative, highrisk, high-gain ideas aimed at Amyotrophic Lateral Sclerosis (ALS) drug or treatment discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. All research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach.
Eligibility: Independent investigators - Faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver obtained through their RPM in RMG prior to the pre-application/letter of intent) may be PI. Early career investigators (defined as independent, non-mentored investigators within 10 years of their last training position e.g., postdoctoral fellowship, medical residency, clinical fellowship as of the application submission deadline) are encouraged to apply.
Not eligible: Instructors, Clinical Instructors, Academic staff-research (i.e., research associates), and postdocs are not eligible for this RFP because Stanford does not consider them to be independent positions.
REQUIRED Pre-Application (Pre-Proposal) Deadline: April 13, 2023 via eBrap
Please include your RPM’s name as business official in the pre-application.
Institutional representative (RPM/RMG or CGO/OSR) Deadline: July 6, 2023
Application Submission Deadline: July 13, 2023 via grants.gov